Good evening :)
$
₹
Neuropace Inc

Neuropace Inc

NPCE

NASDAQ
Asset Logo

Neuropace Inc

NPCE

NASDAQ
$12.486.44% (-0.86)
$
₹
$12.486.44% (-0.86)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Small Cap

With a market cap of $422.5M the stock is ranked 3432

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

35.64
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.57
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-17.86%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 10 analysts reports

Buy
10 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+49.93%

Earnings Growth

+34.29%

Rev. Growth

+0.36%

See Detailed Forecast

Company Profile

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
40.97
40.97
1Y Return
13.03%
13.03%
Buy Reco %
82.14
82.14
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.09
38.09
1Y Return
7.61%
7.61%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
53.29
53.29
1Y Return
10.52%
10.52%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
24.41
24.41
1Y Return
16.08%
16.08%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
32.68
32.68
1Y Return
6.33%
6.33%
Buy Reco %
76.66
76.66
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 49.93% growth, versus a trailing 3-year CAGR of 22.82%.

2026
Current$13.34Baseline
Analyst Target - 1 year
Target$20+49.93%

All values in $

202220232024202520262027$6.51$11.67$16.84Target+49.93%
2026
Current$13.34Baseline
Analyst Target - 1 year
Target$20+49.93%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 0.36% growth, versus a trailing 3-year CAGR of 29.99%.

2025
Current$99.98Baseline
Forecast for Dec 2026
High$101.1+1.11%
Average$100.34+0.36%
Low$99.5-0.49%

All values in $ Million

20212022202320242025202645.1845.5265.4279.9099.98Low-0.49%Average+0.36%High+1.11%
2025
Current$99.98Baseline
Forecast for Dec 2026
High$101.1+1.11%
Average$100.34+0.36%
Low$99.5-0.49%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.66Baseline
Forecast for Dec 2026
High$-0.35+46.97%
Average$-0.43+34.29%
Low$-0.67-1.52%

All values in $

202120222023202420252026-33.99-1.92-1.28-0.95-0.66Low-1.52%Average+34.29%High+46.97%
2025
Current$-0.66Baseline
Forecast for Dec 2026
High$-0.35+46.97%
Average$-0.43+34.29%
Low$-0.67-1.52%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

27.3
-3.4
26.5
-2.7
22
-6.6
22.8
-6.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue18.1219.2521.0621.4622.5223.5227.3526.5822.0622.82
Net Income-8.92-7.51-5.45-5.25-6.58-8.65-3.49-2.72-6.68-6.2
Net Profit Margin-49.24%-39.02%-25.88%-24.45%-29.25%-36.78%-12.78%-10.26%-30.31%-27.16%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Neuropace Inc -35.64-
Abbott Laboratories40.973.721.57
Danaher Corporation38.092.981.29
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare NPCE with any stock or ETF
Compare NPCE with any stock or ETF
Comparing from
NPCE
ABT
DHR
Loading...

Frequently asked questions

  1. Neuropace Inc (NPCE) share price today is $12.48 as of November 5, 2026 at 11:19 PM IST. The stock touched a day high of $13.48 and a day low of $12.48.

  2. Neuropace Inc stock trades on NASDAQ under the ticker symbol NPCE.

  3. Neuropace Inc's market capitalization is $422.53M as of November 5, 2026 at 11:19 PM IST.

  4. Neuropace Inc's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Neuropace Inc's price-to-book (P/B) ratio is 35.64 as of November 5, 2026.

  6. Yes, You can buy Neuropace Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Neuropace Inc shares in three steps: 1. Search Neuropace Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Neuropace Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Neuropace Inc (NPCE) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.8012 shares at the current price of $12.48.

Loading...